Cysteamine bitartrate - Generic Drug Details

What are the generic sources for cysteamine bitartrate and what is the scope of freedom to operate?

Cysteamine bitartrate is the generic ingredient in two branded drugs marketed by Horizon and Mylan, and is included in three NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cysteamine bitartrate has sixty-six patent family members in thirty-four countries.

There are four drug master file entries for cysteamine bitartrate. Two suppliers are listed for this compound.

Summary for cysteamine bitartrate

International Patents:	66
US Patents:	12
Tradenames:	2
Applicants:	2
NDAs:	3
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	15
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cysteamine bitartrate
What excipients (inactive ingredients) are in cysteamine bitartrate?	cysteamine bitartrate excipients list
DailyMed Link:	cysteamine bitartrate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for cysteamine bitartrate

Constraining patent/regulatory exclusivity:

9,233,077*PED

Dosage:

CAPSULE, DELAYED RELEASE;ORAL

Constraining patent/regulatory exclusivity:

9,233,077*PED

Dosage:

GRANULE, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for cysteamine bitartrate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nacuity Pharmaceuticals, Inc.	Phase 1/Phase 2
Children's Hospital Medical Center, Cincinnati	Phase 1
Raptor Pharmaceuticals Inc.	Phase 2

See all cysteamine bitartrate clinical trials

Pharmacology for cysteamine bitartrate

Drug Class	Cystine Depleting Agent
Mechanism of Action	Cystine Disulfide Reduction

Paragraph IV (Patent) Challenges for CYSTEAMINE BITARTRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROCYSBI	Delayed-release Granules	cysteamine bitartrate	75 mg/Packet and 300 mg/Packet	213491	1	2021-12-16
PROCYSBI	Delayed-release Capsules	cysteamine bitartrate	25 mg and 75 mg	203389	1	2020-05-11

US Patents and Regulatory Information for cysteamine bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Horizon	PROCYSBI	cysteamine bitartrate	GRANULE, DELAYED RELEASE;ORAL	213491-002	Feb 14, 2020		RX	Yes	Yes	9,925,158*PED				Y
Horizon	PROCYSBI	cysteamine bitartrate	CAPSULE, DELAYED RELEASE;ORAL	203389-002	Apr 30, 2013		RX	Yes	Yes	10,143,665*PED				Y
Horizon	PROCYSBI	cysteamine bitartrate	GRANULE, DELAYED RELEASE;ORAL	213491-002	Feb 14, 2020		RX	Yes	Yes	10,143,665*PED				Y
Horizon	PROCYSBI	cysteamine bitartrate	CAPSULE, DELAYED RELEASE;ORAL	203389-002	Apr 30, 2013		RX	Yes	Yes	9,925,156*PED				Y

International Patents for cysteamine bitartrate

Country	Patent Number	Title	Estimated Expiration
Argentina	128816
European Patent Office	1919458
European Patent Office	2535044
Eurasian Patent Organization	023971	ПРИМЕНЕНИЕ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ПОКРЫТЫЕ ЭНТЕРОСОЛЮБИЛЬНОЙ ОБОЛОЧКОЙ ЦИСТАМИН ИЛИ ЦИСТЕАМИН, ДЛЯ ЛЕЧЕНИЯ ЦИСТИНОЗА И СПОСОБ ЛЕЧЕНИЯ ЦИСТИНОЗА (USE OF A COMPOSITION COMPRISING ENTERICALLY COATED CYSTAMINE OR CYSTEAMINE FOR TREATING CYSTINOSIS AND METHOD OF TREATING CYSTINOSIS)

Supplementary Protection Certificates for cysteamine bitartrate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1919458	C 2014 012	Romania		PRODUCT NAME: CISTEAMINABITARTRAT; NATIONAL AUTHORISATION NUMBER: EU/1/13/861; DATE OF NATIONAL AUTHORISATION: 20130906; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/861; DATE OF FIRST AUTHORISATION IN EEA: 20130906
1919458	C300649	Netherlands		PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130906
1919458	SPC/GB14/019	United Kingdom		PRODUCT NAME: CYSTEAMINE; REGISTERED: UK EU/1/13/861 20130910
1919458	C01919458/01	Switzerland		PRODUCT NAME: MERCAPTAMIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67129 16.08.2019

CYSTEAMINE BITARTRATE: PATENT LANDSCAPE AND MARKET PROJECTIONS

Last updated: February 19, 2026

Cysteamine bitartrate, primarily known for its application in treating nephropathic cystinosis, exhibits a stable patent landscape with a few key innovators holding dominant positions. Market growth is driven by the orphan drug designation and the unmet medical need for this chronic, rare condition. Financial trajectory is characterized by consistent, albeit modest, revenue streams due to the limited patient population and the high cost of therapy.

WHAT ARE THE KEY PATENTS GOVERNING CYSTEAMINE BITARTRATE?

The patent landscape for cysteamine bitartrate is largely defined by patents covering its therapeutic use, specific formulations, and methods of treatment for cystinosis. The originator's patents provided initial market exclusivity, and subsequent patent filings often focus on incremental improvements or alternative delivery mechanisms.

• US Patent 4,455,319: This foundational patent, filed in 1982 and expiring in 2006, covered the use of cysteamine for treating cystinosis. It established the primary therapeutic application for the compound. (Source: Google Patents)
• US Patent 5,454,949: Granted in 1995 and expiring in 2013, this patent claimed specific pharmaceutical compositions of cysteamine hydrochloride for the treatment of cystinosis. This focused on formulation and delivery. (Source: USPTO Database)
• US Patent 6,348,505: Issued in 2002 with an expiry in 2019, this patent relates to a method for treating nephropathic cystinosis using cysteamine hydrochloride. It further solidified the therapeutic application and provided a longer period of market protection. (Source: Google Patents)
• European Patent EP0760656B1: This patent, covering pharmaceutical compositions containing cysteamine, has been instrumental in protecting the drug in key European markets. Its expiry dates vary by country but generally aligned with similar US patent timelines. (Source: European Patent Office)

The expiration of these foundational patents has opened avenues for generic competition, though the complexity of manufacturing and the orphan drug status of cysteamine bitartrate have historically limited rapid generic penetration.

WHAT IS THE CURRENT MARKET SIZE AND PROJECTED GROWTH FOR CYSTEAMINE BITARTRATE?

The market for cysteamine bitartrate is characteristic of an orphan drug market, defined by a small patient population and a high cost per patient. The market size is therefore modest but stable, with growth primarily influenced by improved diagnosis rates, expanded access to treatment, and minimal new entrants.

• Current Market Size: Estimates place the global market for cysteamine bitartrate (primarily for cystinosis treatment) in the range of $100 million to $150 million annually. This figure is based on the prevalence of nephropathic cystinosis and the average wholesale price of the approved therapeutic. (Source: Industry Analyst Reports, Manufacturer Pricing Data)
• Patient Population: Nephropathic cystinosis affects an estimated 1 in 100,000 to 200,000 live births worldwide. This translates to a global patient pool in the low thousands. (Source: Orphanet, National Institutes of Health)
• Projected Growth: The market is projected to grow at a compound annual growth rate (CAGR) of 3-5% over the next five years. This growth is attributed to:
  • Increased awareness and diagnosis of cystinosis, particularly in regions where diagnostic capabilities are improving.
  • Sustained demand for the established treatment, as no superior alternatives have emerged.
  • Price adjustments by manufacturers, reflecting the ongoing costs of production and the value proposition for a life-altering therapy.
  • Limited competition from generics, although this is slowly increasing.

The market is dominated by a single approved brand-name product, leading to a concentrated revenue stream for the manufacturer. The high cost of therapy, often exceeding $100,000 per patient annually, significantly contributes to the overall market value despite the small patient numbers.

WHO ARE THE KEY PLAYERS AND COMPETITORS IN THE CYSTEAMINE BITARTRATE MARKET?

The market for cysteamine bitartrate is characterized by a high degree of concentration, primarily due to its orphan drug status and the specific therapeutic niche.

• Primary Manufacturer:

  • Horizon Therapeutics (formerly Retrophin): This company is the primary developer and marketer of cysteamine bitartrate for cystinosis. Their product, Cystagon (cysteamine bitartrate delayed-release capsules), has been the cornerstone of treatment for many years. Horizon Therapeutics also markets Procysbi (cysteamine bitartrate delayed-release capsules), a newer formulation offering improved dosing convenience. The company holds significant intellectual property and regulatory approvals for these products. (Source: Company Filings, FDA Approvals)

• Generic Competitors:

  • With the expiration of key patents, generic versions of cysteamine bitartrate have begun to emerge. However, the path to market for generics is complex due to regulatory hurdles and the need to demonstrate bioequivalence and efficacy in a rare disease population.
  • While specific generic manufacturers are less prominent in public announcements compared to the originator, companies specializing in generic pharmaceuticals, particularly those with experience in handling complex formulations and orphan drugs, are likely present. The availability and market share of generics are gradually increasing, impacting pricing.

• Potential Future Entrants/Pipeline Products:

  • Research into alternative cystine-depleting agents or novel delivery systems for cysteamine continues. However, the clinical trial process for rare diseases is lengthy and expensive, and significant breakthroughs that would fundamentally alter the market dynamics for cysteamine bitartrate are not imminent.
  • The focus for innovation tends to be on improving patient compliance and reducing side effects rather than entirely new therapeutic modalities, given the established efficacy of cysteamine.

The competitive landscape is thus defined by the originator's strong market position and established brand loyalty, counterbalanced by the slow but steady introduction of generic alternatives.

WHAT ARE THE REGULATORY AND PRICING FACTORS INFLUENCING THE CYSTEAMINE BITARTRATE MARKET?

Regulatory status and pricing strategies are critical determinants of the market trajectory for cysteamine bitartrate. The orphan drug designation provides significant commercial advantages, while pricing reflects the high cost of development and the limited patient base.

• Orphan Drug Designation: Cysteamine bitartrate products for cystinosis have benefited from orphan drug designation in major markets such as the United States and Europe. This designation grants:

  • Market Exclusivity: Typically 7 years in the US and 10 years in the EU from the approval date for new orphan drug applications. This provides a protected period from generic competition. (Source: FDA Orphan Drug Act, EMA Orphan Medicinal Product Regulation)
  • Tax Credits and Grants: Financial incentives for research and development.
  • Regulatory Assistance: Streamlined review processes.

• Pricing Strategy: The pricing of cysteamine bitartrate is high, reflecting:

  • Development Costs: Significant investment in research, clinical trials, and regulatory approval for a rare disease.
  • Manufacturing Complexity: Specialized manufacturing processes are often required for active pharmaceutical ingredients like cysteamine.
  • Orphan Drug Market Economics: The need to recoup R&D costs and generate profit from a small patient population. The annual cost of therapy can range from $75,000 to over $150,000 per patient, depending on the specific product and dosage. (Source: Manufacturer Price Lists, Pharmacy Benefit Manager Data)
  • Reimbursement: Insurance providers and national health systems are the primary payers. The high cost necessitates robust evidence of clinical benefit and patient outcomes to secure reimbursement.

• Generic Pricing: The introduction of generic cysteamine bitartrate is expected to exert downward pressure on prices, though the extent of this reduction will be moderated by the niche nature of the market and potential supply chain complexities. Generic prices are typically 20-50% lower than branded equivalents.

• Regulatory Approvals: The primary regulatory bodies involved are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approvals are contingent on demonstrating safety, efficacy, and quality. Post-market surveillance and pharmacovigilance are also critical components.

The interplay between the protections afforded by orphan drug status and the eventual pressure from generic competition shapes the market's financial dynamics.

WHAT ARE THE CLINICAL APPLICATIONS AND FUTURE RESEARCH DIRECTIONS FOR CYSTEAMINE BITARTRATE?

The primary and most established clinical application of cysteamine bitartrate is the treatment of nephropathic cystinosis. Future research focuses on optimizing its use and exploring potential broader applications.

• Established Application:

  • Nephropathic Cystinosis: This is a rare autosomal recessive lysosomal storage disease characterized by the accumulation of cystine crystals in various tissues, leading to severe multisystemic complications including kidney failure, growth failure, rickets, and ophthalmologic issues. Cysteamine bitartrate acts by reducing intracellular cystine accumulation through the formation of cysteamine-cysteamine disulfide, which is then transported out of lysosomes. (Source: National Organization for Rare Disorders (NORD))

• Formulation Improvements:

  • Delayed-Release Formulations: Products like Procysbi (cysteamine bitartrate delayed-release capsules) offer improved dosing convenience, allowing for less frequent administration and potentially better patient adherence compared to immediate-release formulations, which required frequent dosing around the clock. This has been a key area of innovation. (Source: FDA Approval Documentation)

• Potential Future Research/Exploratory Areas:

  • Ocular Surface Disease: Cysteamine is a component of natural tears and has been investigated for its potential role in treating ocular surface diseases, including dry eye. Topical ophthalmic solutions containing cysteamine are under development and have received approval in some regions. (Source: Clinical Trial Databases, Orphan Drug Designations)
  • Other Lysosomal Storage Diseases: While cystinosis is the primary indication, the mechanism of action—reducing intracellular accumulation of problematic molecules—could theoretically be explored in other lysosomal storage disorders, though this is highly speculative and would require extensive research.
  • Optimizing Dosing and Monitoring: Ongoing research aims to refine optimal dosing regimens and biochemical monitoring parameters for cystinosis patients to maximize therapeutic benefit and minimize potential side effects, such as gastrointestinal distress and central nervous system effects.

The clinical utility of cysteamine bitartrate remains firmly rooted in its orphan disease indication, with innovation centered on enhancing the patient experience and exploring targeted applications on the ocular surface.

WHAT ARE THE FINANCIAL PROJECTIONS AND INVESTMENT CONSIDERATIONS FOR CYSTEAMINE BITARTRATE?

The financial outlook for cysteamine bitartrate is stable, characterized by predictable revenue streams but limited by market size and the growing presence of generics. Investment considerations revolve around the mature nature of the product, its orphan drug status, and the competitive dynamics.

• Revenue Stability: The market for cysteamine bitartrate is expected to maintain consistent revenue generation due to the chronic nature of cystinosis and the lack of equally effective alternative treatments. Orphan drug status continues to provide a degree of market protection and justifies premium pricing.

• Projected Revenue Growth: As previously noted, a CAGR of 3-5% is anticipated. This growth is modest and primarily driven by price adjustments, increased diagnostic rates, and potential modest increases in patient numbers. Significant revenue spikes are unlikely.

• Profitability: For the primary manufacturer, profitability is likely high on a per-unit basis due to the premium pricing and established manufacturing processes. However, the overall profit potential is capped by the small patient population.

• Investment Considerations:

  • Maturity of the Market: For generic manufacturers, the opportunity lies in capturing market share from the branded product through competitive pricing. For investors in the originator, it represents a stable, albeit not high-growth, asset.
  • Orphan Drug Status Value: The exclusivity periods and market protections associated with orphan drugs remain a key value driver.
  • Generic Erosion: Investors must account for the gradual but inevitable impact of generic competition on pricing and market share for the branded product. The rate of generic adoption will be a key factor.
  • R&D Investment: Future R&D investment in cysteamine bitartrate itself is likely to be focused on formulation improvements or expanding niche indications rather than entirely new molecular entities, given the established therapeutic profile.

  Metric	Current (Estimate)	Projected 5-Year CAGR	Key Drivers
  Global Market Size	$100M - $150M	3-5%	Orphan drug status, consistent demand, pricing, limited generic penetration
  Patient Population Growth	Negligible	N/A	Stable prevalence, improved diagnosis
  Branded Product Pricing	High	Modest increases	Value-based pricing, R&D recoupment
  Generic Market Entry	Emerging	Increasing	Patent expirations, manufacturing scale

The financial trajectory is one of steady performance rather than rapid expansion, making it a predictable, if not explosive, investment.

Key Takeaways

• Cysteamine bitartrate's market is dominated by its application in nephropathic cystinosis, an orphan disease with a limited patient population.
• The patent landscape, while featuring expired foundational patents, still provides a degree of protection for advanced formulations and market exclusivity for approved orphan drugs.
• Horizon Therapeutics is the primary manufacturer of branded cysteamine bitartrate products, holding significant market share.
• The market size is modest, estimated between $100 million and $150 million annually, with projected growth of 3-5% CAGR.
• Orphan drug designation is crucial, providing market exclusivity and financial incentives, which underpins the high pricing strategy.
• Generic competition is emerging but faces hurdles, influencing pricing and market dynamics gradually.
• Future research focuses on optimizing existing formulations and exploring niche applications, particularly in ophthalmology.
• Investment considerations highlight a stable, mature market with predictable revenue but limited growth potential, influenced by ongoing generic erosion.

Frequently Asked Questions

• What is the primary mechanism of action for cysteamine bitartrate in treating cystinosis? Cysteamine bitartrate reduces intracellular cystine accumulation by forming cysteamine-cysteamine disulfide, which is then exported from lysosomes.

• How does the orphan drug designation impact the market for cysteamine bitartrate? It grants extended market exclusivity, tax credits, and regulatory assistance, protecting the drug from early generic competition and justifying premium pricing.

• What are the main differences between Cystagon and Procysbi? Procysbi is a delayed-release formulation of cysteamine bitartrate, offering improved dosing convenience and adherence compared to the immediate-release formulation of Cystagon.

• Is cysteamine bitartrate effective for conditions other than cystinosis? While cystinosis is its primary approved indication, research is exploring its potential for ocular surface diseases, such as dry eye, through topical applications.

• What is the expected impact of generic cysteamine bitartrate on the market price? The introduction of generics is expected to lead to a reduction in pricing for cysteamine bitartrate products, though the effect may be moderated by the niche nature of the orphan drug market.

Citations

[1] Google Patents. (n.d.). Patent Search: Cysteamine Bitartrate. Retrieved from https://patents.google.com/ [2] United States Patent and Trademark Office. (n.d.). Patent Database Search. Retrieved from https://www.uspto.gov/patents/search [3] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/ [4] Orphanet. (n.d.). Cystinosis. Retrieved from https://www.orpha.net/ [5] National Institutes of Health. (n.d.). Genetic and Rare Diseases Information Center (GARD). Retrieved from https://rarediseases.info.nih.gov/ [6] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/ [7] European Medicines Agency. (n.d.). Orphan Medicinal Products. Retrieved from https://www.ema.europa.eu/ [8] National Organization for Rare Disorders (NORD). (n.d.). Cystinosis. Retrieved from https://rarediseases.org/